AMGN vs NVS
AMGN: A global biotechnology innovator producing biologics, monoclonal antibodies, and small molecules across oncology, cardiovascular, inflammation, and bone health, navigating complex U.S. Medicare pricing pressures. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | AMGN | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $385.16 | $156.11 | |
| Market cap as of 2026-08-03 | $207.9B | $232.1B | |
| P/E as of 2026-08-03 | 26.78 | 22.53 | NVS lower |
| PEG as of 2026-08-03 | 5.48 | 3.66 | NVS lower |
| Net margin as of 2026-08-03 | +21.0% | +22.5% | NVS higher |
| Gross margin as of 2026-08-03 | +74.0% | +75.0% | NVS higher |
| Operating margin as of 2026-08-03 | +28.8% | +29.9% | NVS higher |
| ROE as of 2026-08-03 | +89.4% | +29.9% | AMGN higher |
| ROA as of 2026-08-03 | +8.6% | +11.1% | NVS higher |
| Debt / equity as of 2026-08-03 | 6.24 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-08-03 | +9.1% | +3.3% | AMGN higher |
| Revenue CAGR (3y) SEC XBRL | +11.8% | n/a | |
| Dividend yield as of 2026-08-03 | +2.6% | +2.9% | NVS higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.43 | 1.17 | |
| 1-year return as of 2026-07-31 close | +30.5% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.